argenex Stock Gets Increased EPS Estimate from HC Wainwright

argenex SE (NASDAQ:ARGX) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for argenex in a research report issued on Friday, October 23rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $27.76 per share for the year, up from their prior forecast of $26.27. HC Wainwright currently has a “Buy” rating and a $1,202.00 target price on the stock. The consensus estimate for argenex’s current full-year earnings is $25.79 per share. HC Wainwright also issued estimates for argenex’s Q4 2026 earnings at $7.13 EPS, Q1 2027 earnings at $6.54 EPS and FY2027 earnings at $33.52 EPS.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating the consensus estimate of $7.44 by $0.36. The business had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%.

Several other brokerages also recently issued reports on ARGX. Citigroup boosted their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. Guggenheim lowered their price target on argenex from $1,185.00 to $1,120.00 and set a “buy” rating on the stock in a report on Friday. Citizens Jmp upped their price target on argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 18th. Finally, Barclays reissued a “buy” rating on shares of argenex in a research report on Monday, September 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and a consensus target price of $1,142.37.

argenex Stock Performance

argenex stock opened at $869.33 on Tuesday. argenex has a 52 week low of $661.85 and a 52 week high of $1,072.75. The firm has a market capitalization of $54.67 billion, a price-to-earnings ratio of 30.33, a P/E/G ratio of 0.89 and a beta of 0.44. The company has a 50 day moving average price of $953.35 and a 200 day moving average price of $853.01.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ARGX. WPG Advisers LLC grew its holdings in shares of argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after buying an additional 13 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in argenex by 3.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock valued at $363,000 after acquiring an additional 13 shares in the last quarter. Mather Group LLC. lifted its stake in argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after acquiring an additional 13 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in argenex by 2.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 500 shares of the company’s stock worth $479,000 after acquiring an additional 13 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in argenex by 2.8% during the 1st quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock worth $382,000 after acquiring an additional 14 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.